Stivarga Regulatory Post-Marketing Surveillance Study in Korea

• Status: Completed
• Trial end date: 2019-05-07
• Target enrollment: 0
• Participant gender: All

Summary

To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

• Inclusion Criteria:

• Signed and dated informed consent

• Patients diagnosed with histologically confirmed metastatic colorectal cancer and/or metastatic or unresectable locally advanced gastrointestinal stromal tumors and/or HCC who have been previously treated with sorafenib by physician

• Patients who are prescribed with Stivarga tablet 40mg(Regorafenib) for the first time

• Exclusion Criteria:

• Patients participating in an investigational program with interventions outside of routine clinical practice

• All contra-indications according to the local marketing authorization have to be considered.